These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10458245)

  • 1. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?
    Murray CK; Estey E; Paietta E; Howard RS; Edenfield WJ; Pierce S; Mann KP; Bolan C; Byrd JC
    J Clin Oncol; 1999 Jan; 17(1):293-7. PubMed ID: 10458245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
    Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
    J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of CD56 antigen expression in acute myeloid leukemia.
    Di Bona E; Sartori R; Zambello R; Guercini N; Madeo D; Rodeghiero F
    Haematologica; 2002 Mar; 87(3):250-6. PubMed ID: 11869936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients.
    Breccia M; De Propris MS; Minotti C; Stefanizzi C; Raponi S; Colafigli G; Latagliata R; Guarini A; Foà R
    Leuk Res; 2014 Feb; 38(2):194-7. PubMed ID: 24296270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute promyelocytic leukemia is a distinct subset of acute myelocytic leukemia with unique clinicopathologic characteristics including longer duration of relapse free survival: experience in 13 cases.
    Lee KH; Kim DH; Lee JS; Suh CW; Kim SW; Kim SB; Lee JH; Doh BS; Chi HS; Lee MS
    J Korean Med Sci; 1994 Dec; 9(6):437-43. PubMed ID: 7786438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and laboratory features of patients with CD34(+) acute promyelocytic leukemia].
    Liang JY; Wu DP; Liu YJ; Ma QF; Xue YQ; Zhu MQ; Chen ZX
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):196-8. PubMed ID: 19615259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia.
    Ito S; Ishida Y; Oyake T; Satoh M; Aoki Y; Kowata S; Uchiyama T; Enomoto S; Sugawara T; Numaoka H; Suzuki K; Murai K
    Leuk Lymphoma; 2004 Sep; 45(9):1783-9. PubMed ID: 15223636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
    Raspadori D; Damiani D; Michieli M; Stocchi R; Gentili S; Gozzetti A; Masolini P; Michelutti A; Geromin A; Fanin R; Lauria F
    Haematologica; 2002 Nov; 87(11):1135-40. PubMed ID: 12414342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of CD56 expression and relapse rate in acute myeloid leukemia patients with t(8;21) in Taiwan.
    Hsiao CH; Tang JL; Yao M; Tsay W; Wang CH; Chen YC; Shen MC; Tien HF
    J Formos Med Assoc; 2002 Jun; 101(6):393-8. PubMed ID: 12189644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
    Montesinos P; Rayón C; Vellenga E; Brunet S; González J; González M; Holowiecka A; Esteve J; Bergua J; González JD; Rivas C; Tormo M; Rubio V; Bueno J; Manso F; Milone G; de la Serna J; Pérez I; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; ;
    Blood; 2011 Feb; 117(6):1799-805. PubMed ID: 21148082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical and laboratory features of acute promyelocytic leukemia: an analysis of 513 cases].
    Liang JY; Wu DP; Liu YJ; Ma QF; Gong JX; Zhu MQ; Xue YQ; Chen ZX
    Zhonghua Nei Ke Za Zhi; 2008 May; 47(5):389-92. PubMed ID: 18953948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis.
    Kaito K; Katayama T; Masuoka H; Nishiwaki K; Sano K; Sekiguchi N; Hagino T; Kobayashi M
    Clin Lab Haematol; 2005 Oct; 27(5):307-11. PubMed ID: 16178910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia.
    Candoni A; Damiani D; Michelutti A; Masolini P; Michieli M; Michelutti T; Geromin A; Fanin R
    Eur J Haematol; 2003 Jul; 71(1):1-8. PubMed ID: 12801292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution.
    Pollicardo N; O'Brien S; Estey EH; al-Bitar M; Pierce S; Keating M; Kantarjian HM
    Leukemia; 1996 Jan; 10(1):27-31. PubMed ID: 8558933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants.
    Sucić M; Zadro R; Burazer B; Labar B; Nemet D; Mrsić M; Aurer I; Mrsić S; Hitrec V; Boban D; Marković-Glamocak M; Batinić D; Uzarević B; Stavljenić-Rukavina A
    J Hematother Stem Cell Res; 2002 Dec; 11(6):941-50. PubMed ID: 12590709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
    Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
    Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy.
    Elliott MA; Letendre L; Tefferi A; Hogan WJ; Hook C; Kaufmann SH; Pruthi RK; Pardanani A; Begna KH; Ashrani AA; Wolanskyj AP; Al-Kali A; Litzow MR
    Eur J Haematol; 2012 Mar; 88(3):237-43. PubMed ID: 22023492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
    Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
    Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
    Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.